[
  {
    "ts": null,
    "headline": "FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS",
    "summary": "The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has passed with no clarity on when the decision will move forward again.",
    "url": "https://finnhub.io/api/news?id=5b68a6a0d1e4e6384f95ff881555072a0e5c2882dc631d987b355559b8100ded",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743709147,
      "headline": "FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS",
      "id": 133704627,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has passed with no clarity on when the decision will move forward again.",
      "url": "https://finnhub.io/api/news?id=5b68a6a0d1e4e6384f95ff881555072a0e5c2882dc631d987b355559b8100ded"
    }
  },
  {
    "ts": null,
    "headline": "Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna",
    "summary": "In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).  If Pfizer and Moderna can bounce back, purchasing their shares now might be a great move -- but which is the more attractive option?  Pfizer has made important moves in the past few years that could pay off down the line.",
    "url": "https://finnhub.io/api/news?id=29d32d85bc67231ca2e8c35213479ad89c7a010cf362fbcf56839b7552f1802a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743683400,
      "headline": "Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna",
      "id": 133697787,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).  If Pfizer and Moderna can bounce back, purchasing their shares now might be a great move -- but which is the more attractive option?  Pfizer has made important moves in the past few years that could pay off down the line.",
      "url": "https://finnhub.io/api/news?id=29d32d85bc67231ca2e8c35213479ad89c7a010cf362fbcf56839b7552f1802a"
    }
  },
  {
    "ts": null,
    "headline": "Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks",
    "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).",
    "url": "https://finnhub.io/api/news?id=f5fd93fd56e5b7b9ca7623b8b7214c2216284672bd9de69eac3336dd31fb19d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743671314,
      "headline": "Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks",
      "id": 133697756,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).",
      "url": "https://finnhub.io/api/news?id=f5fd93fd56e5b7b9ca7623b8b7214c2216284672bd9de69eac3336dd31fb19d3"
    }
  },
  {
    "ts": null,
    "headline": "FDA News Just Shook Moderna. Is the Stock One to Avoid or a Bad-News Buy?",
    "summary": "Moderna (NASDAQ: MRNA) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later stages of the coronavirus pandemic.  Now, the biotech is trying to show the world that it can expand beyond coronavirus prevention as it has a full pipeline of programs ranging from latent viruses and rare diseases to cancer.  In fact, its cancer vaccine is in late-stage development and has generated positive clinical data.",
    "url": "https://finnhub.io/api/news?id=dd0bb5374a6495e79cb7065ccc97c27b358ddb5ff94c3fb0016e86da8e010e99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743667680,
      "headline": "FDA News Just Shook Moderna. Is the Stock One to Avoid or a Bad-News Buy?",
      "id": 133695166,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (NASDAQ: MRNA) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later stages of the coronavirus pandemic.  Now, the biotech is trying to show the world that it can expand beyond coronavirus prevention as it has a full pipeline of programs ranging from latent viruses and rare diseases to cancer.  In fact, its cancer vaccine is in late-stage development and has generated positive clinical data.",
      "url": "https://finnhub.io/api/news?id=dd0bb5374a6495e79cb7065ccc97c27b358ddb5ff94c3fb0016e86da8e010e99"
    }
  }
]